{"id":41172,"date":"2025-09-11T16:31:08","date_gmt":"2025-09-11T08:31:08","guid":{"rendered":"https:\/\/flcube.com\/?p=41172"},"modified":"2025-09-11T16:31:08","modified_gmt":"2025-09-11T08:31:08","slug":"novartis-secures-tabrecta-approval-in-china-for-metex14-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41172","title":{"rendered":"Novartis Secures Tabrecta Approval in China for METex14 NSCLC"},"content":{"rendered":"\n<p>Swiss pharmaceutical giant Novartis (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE: NVS<\/a>) announced that its MET\u2011receptor tyrosine kinase inhibitor <strong>Tabrecta (capmatinib hydrochloride tablets)<\/strong> has received formal approval in China for a new therapeutic indication. The drug is now licensed to treat <strong>adult patients with locally advanced or metastatic non\u2011small cell lung cancer (NSCLC) carrying MET exon\u202f14 skipping mutations<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-the-approval-matters\">Why the Approval Matters<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targeted Precision<\/strong> \u2013 MET exon\u202f14 skipping mutations occur in ~3\u20135\u202f% of NSCLC patients, a subgroup that historically has limited treatment options.<\/li>\n\n\n\n<li><strong>Expedited Access<\/strong> \u2013 The approval builds on Tabrecta\u2019s 2024 clearance for first\u2011line use in the same patient population, now expanding its clinical utility to all disease stages.<\/li>\n\n\n\n<li><strong>Competitive Edge<\/strong> \u2013 Novartis positions itself as a leader in precision oncology within China, a market worth over $70\u202fbillion in oncology sales.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-tabrecta-s-pharmacology\">Tabrecta\u2019s Pharmacology<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Orally bioavailable<\/strong> \u2013 Patients can take the drug at home, improving adherence.<\/li>\n\n\n\n<li><strong>Highly selective MET inhibition<\/strong> \u2013 Suppresses MET phosphorylation and downstream pathways (PI3K\/AKT, RAS\u2011RAF\u2011MEK), curbing tumor proliferation and migration.<\/li>\n\n\n\n<li><strong>Potent anti\u2011tumor activity<\/strong> \u2013 Clinical trials demonstrate significant objective response rates in METex14\u2011positive NSCLC, with durable disease control.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-pathway\">Regulatory Pathway<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Step<\/th><th>Date<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td>Initial filing (Phase\u202f3 data)<\/td><td>2023<\/td><td>Accepted for review<\/td><\/tr><tr><td>2024 first\u2011line approval<\/td><td>2024<\/td><td>Approved for treatment of first\u2011line, METex14\u2011positive NSCLC<\/td><\/tr><tr><td>2025 expanded indication<\/td><td>Sept\u202f11\u202f2025<\/td><td>Approved for all stages of locally advanced or metastatic METex14 NSCLC<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The Chinese Food and Drug Administration (CFDA) highlighted the drug\u2019s favorable benefit\u2011risk profile and the unmet need in the targeted patient cohort.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-amp-commercial-implications\">Market &amp; Commercial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pricing &amp; Reimbursement<\/strong> \u2013 Novartis is negotiating a tiered pricing strategy aligned with China\u2019s national drug price guidelines, aiming for broad reimbursement coverage.<\/li>\n\n\n\n<li><strong>Supply Chain<\/strong> \u2013 Production is already scaled to meet projected demand, with a local manufacturing partner in Shanghai ensuring supply reliability.<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong> \u2013 The approval positions Tabrecta against other MET inhibitors (e.g., capmatinib\u2011brand\u2011free alternatives) and broad\u2011spectrum TKIs, potentially capturing a significant share of the precision oncology market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its MET\u2011receptor tyrosine kinase inhibitor Tabrecta (capmatinib&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41173,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,140,865,15,33],"class_list":["post-41172","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-novartis","tag-nyse-nvs","tag-product-approvals","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novartis Secures Tabrecta Approval in China for METex14 NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its MET\u2011receptor tyrosine kinase inhibitor Tabrecta (capmatinib hydrochloride tablets) has received formal approval in China for a new therapeutic indication. The drug is now licensed to treat adult patients with locally advanced or metastatic non\u2011small cell lung cancer (NSCLC) carrying MET exon\u202f14 skipping mutations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41172\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis Secures Tabrecta Approval in China for METex14 NSCLC\" \/>\n<meta property=\"og:description\" content=\"Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its MET\u2011receptor tyrosine kinase inhibitor Tabrecta (capmatinib hydrochloride tablets) has received formal approval in China for a new therapeutic indication. The drug is now licensed to treat adult patients with locally advanced or metastatic non\u2011small cell lung cancer (NSCLC) carrying MET exon\u202f14 skipping mutations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41172\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-11T08:31:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1108.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41172#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41172\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis Secures Tabrecta Approval in China for METex14 NSCLC\",\"datePublished\":\"2025-09-11T08:31:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41172\"},\"wordCount\":331,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41172#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1108.webp\",\"keywords\":[\"Cancer\",\"Novartis\",\"NYSE: NVS\",\"Product approvals\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41172#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41172\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41172\",\"name\":\"Novartis Secures Tabrecta Approval in China for METex14 NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41172#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41172#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1108.webp\",\"datePublished\":\"2025-09-11T08:31:08+00:00\",\"description\":\"Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its MET\u2011receptor tyrosine kinase inhibitor Tabrecta (capmatinib hydrochloride tablets) has received formal approval in China for a new therapeutic indication. The drug is now licensed to treat adult patients with locally advanced or metastatic non\u2011small cell lung cancer (NSCLC) carrying MET exon\u202f14 skipping mutations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41172#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41172\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41172#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1108.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1108.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novartis Secures Tabrecta Approval in China for METex14 NSCLC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41172#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis Secures Tabrecta Approval in China for METex14 NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis Secures Tabrecta Approval in China for METex14 NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its MET\u2011receptor tyrosine kinase inhibitor Tabrecta (capmatinib hydrochloride tablets) has received formal approval in China for a new therapeutic indication. The drug is now licensed to treat adult patients with locally advanced or metastatic non\u2011small cell lung cancer (NSCLC) carrying MET exon\u202f14 skipping mutations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41172","og_locale":"en_US","og_type":"article","og_title":"Novartis Secures Tabrecta Approval in China for METex14 NSCLC","og_description":"Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its MET\u2011receptor tyrosine kinase inhibitor Tabrecta (capmatinib hydrochloride tablets) has received formal approval in China for a new therapeutic indication. The drug is now licensed to treat adult patients with locally advanced or metastatic non\u2011small cell lung cancer (NSCLC) carrying MET exon\u202f14 skipping mutations.","og_url":"https:\/\/flcube.com\/?p=41172","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-11T08:31:08+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1108.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41172#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41172"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis Secures Tabrecta Approval in China for METex14 NSCLC","datePublished":"2025-09-11T08:31:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41172"},"wordCount":331,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41172#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1108.webp","keywords":["Cancer","Novartis","NYSE: NVS","Product approvals","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41172#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41172","url":"https:\/\/flcube.com\/?p=41172","name":"Novartis Secures Tabrecta Approval in China for METex14 NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41172#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41172#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1108.webp","datePublished":"2025-09-11T08:31:08+00:00","description":"Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its MET\u2011receptor tyrosine kinase inhibitor Tabrecta (capmatinib hydrochloride tablets) has received formal approval in China for a new therapeutic indication. The drug is now licensed to treat adult patients with locally advanced or metastatic non\u2011small cell lung cancer (NSCLC) carrying MET exon\u202f14 skipping mutations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41172#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41172"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41172#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1108.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1108.webp","width":1080,"height":608,"caption":"Novartis Secures Tabrecta Approval in China for METex14 NSCLC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41172#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis Secures Tabrecta Approval in China for METex14 NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1108.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41172"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41172\/revisions"}],"predecessor-version":[{"id":41174,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41172\/revisions\/41174"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41173"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}